Galmed Pharmaceuticals Ltd. reported a net loss of $5.5 million for the nine months ending September 30, 2025, with cash and cash equivalents totaling $3.3 million as of the same date. The filing, submitted on November 26, 2025, includes interim financial statements and highlights ongoing investment needs for development projects.